Feinberg Child Study Center, Schneider Children's Medical Center of Israel and Sackler Faculty of Medicine, Tel Aviv University, 14 Kaplan Street, 49202, Petach-Tikva, Tel Aviv, Israel.
J Neural Transm (Vienna). 2010 Jan;117(1):139-45. doi: 10.1007/s00702-009-0330-x. Epub 2009 Oct 23.
To assess the effectiveness and tolerability of citalopram for the acute treatment of children and adolescents suffering from depression and/or anxiety disorders. As much as 78 outpatients, aged 7-18 years with a diagnosis of depressive and/or anxiety disorder, completed an 8-week open trial with citalopram (20-40 mg/day). Outcome, side effects and suicidality were assessed weekly to bi-weekly using appropriate rating scales. At endpoint 56% of subjects were found to be responders (Clinical Global Impression-Improvement [CGI-I] Scale <or= 2). Subjects with less severe psychopathology and subjects with anxiety disorders showed a more favorable response. As much as 43% of depressed and 51% of anxious subjects had a 50% or greater reduction in scores on our secondary outcome measures, Children's Depression Rating Scale-Revised (CDRS-R) and Screen for Child Anxiety Related Emotional Disorders (SCARED). Most reported adverse events were mild to moderate and did not affect medication adherence. No increase in suicidality was observed during the study. Citalopram was moderately effective, generally well tolerated and safe for the acute treatment of depressed and anxious children and adolescents.
评估西酞普兰治疗儿童和青少年抑郁症和/或焦虑症的急性疗效和耐受性。78 名 7-18 岁的门诊患者被诊断为抑郁症和/或焦虑症，完成了为期 8 周的西酞普兰（20-40mg/天）开放性试验。使用适当的评定量表每周至每两周评估一次疗效、副作用和自杀意念。在终点时，56%的患者被认为是有反应者（临床总体印象-改善量表 [CGI-I] <或= 2）。精神病理学程度较轻的患者和焦虑症患者的反应更好。多达 43%的抑郁患者和 51%的焦虑患者在我们的次要疗效指标，儿童抑郁评定量表修订版（CDRS-R）和儿童焦虑相关情绪障碍筛查表（SCARED）上的评分降低了 50%或更多。大多数报告的不良事件为轻至中度，不影响药物依从性。研究期间未观察到自杀意念增加。西酞普兰对治疗抑郁和焦虑的儿童和青少年具有中等疗效，通常耐受性良好且安全。
